Table 4.

Response to NGR-hTNF/RCHOP, consolidation, relapse, and survival

Response to NGR-hTNF/R-CHOP	Consolidation	Response to consolidation	Treatment failure	TTTF, mo*	Status	Survival, mo*
PD	None	—	Yes	4	DoD	5
CR	Lenalidomide	CR	Yes	11	DoD	11
PD	None	—	Yes	4	DoD	14
CR	WBRT > lenalidomide	CR	Yes	6	DoD	18
PD	None	—	Yes	4	DoD	6
CR	WBRT > lenalidomide	CR	Yes	9	DoD	22
CR	ASCT > WBRT	CR	Yes	6	Alive	31
CR	ASCT > lenalidomide	CR	Yes	17	Alive	30
CR	ASCT	CR	Yes	9	DoD	11
PR	WBRT	CR	No	10	DUC	10
CR	ASCT	CR	Yes	6	DoD	7
CR	ASCT	CR	No	25	Alive	25
PD	None	—	Yes	1	DoD	2
PD	None	—	Yes	1	DoD	2
CR	None	—	Yes	13	DoD	19
PR	WBRT	CR	Yes	10	DoD	11
PR	WBRT	PR	Yes	5	DoD	7
PR	WBRT	PR	Yes	5	DoD	7
PR	None	—	Yes	5	DoD	6
PD	None	—	Yes	0	DoD	1
PR	None	—	Yes	5	DoD	7
PR	None	—	Yes	6	DoD	9
PR	WBRT	PR	Yes	7	DoD	8
CR	ASCT	CR	No	17	Alive	17
PD	None	—	Yes	1	DoD	3
PR	WBRT	PR	Yes	3	DoD	6
CR	ASCT	CR	No	14	Alive	14
PR	WBRT	CR	No	14	Alive	14

Patients are reported in the same order as in Table 2.

DoD, death [as a result] of disease; DUC, death [as a result of an] unknown cause.

^*TTTF, time to treatment failure and survival were estimated from trial registration.